Clinicians reported that five patients naïve to vigabatrin discontinued
treatment because of VFDs; their vigabatrin exposures ranged from
13 months to 3.3 years, which is an expected finding for prolonged
vigabatrin exposure and is similar to previous findings [20]. Three additional
patients reported to have discontinued treatment with VFD had
received previous vigabatrin treatment or were continuing treatment
when entering the REMS program. The ophthalmologic findings for the
much larger group of patients who did not discontinue treatment because
of VFD are being reported elsewhere.